In this study, we examined resistance mechanisms to FGFR inhibition in two contexts – acquired resistance following long term exposure, and rapidly following 4–72 h treatment – in two bladder cancer cell lines harbouring FGFR3-fusions that had not been previously characterized in terms of response to FGFR inhibition. The gene discussed is FGFR3; the disease is urinary bladder carcinoma.